Telavancin structure

Telavancin Complicated skin and skin structure infections Theravance (South San Francisco, CA) 9/11/2009... 

Vancomycin, a natural product that was first approved in 1955, is still the prototype for structural variations with the same mechanism of action the binding to the terminal L-Lys-D-Ala-D-Ala tripeptide in Gram-positive cell wall biosynthesis. The compounds below are semi-synthetic modifications of the same basic structural class (glycopeptides) as the prototype vancomycin, thus following in the chemical footsteps of the (1-lactams currently, there are three semi-synthetic glycopeptides, oritavancin 39, telavancin 40 and dalba-vancin 41, in late stage clinical development. 

Comparative studies The results of the combined ATLAS trials, in which telavancin and vancomycin were compared in the treatment of complicated skin and skin-structure infections, have been reviewed [49, 50 ]. Clinical efficacy was comparable. Adverse events that were significantly more common with telavancin than vancomycin included taste disturbance (34% versus 6.6%), nausea (27% versus 15%), vomiting (14% versus 7A%), foamy urine (13% versus 2.9%), constipation (10% versus 6.5%), and renal impairment (6.3% versus 2.2%) QTc interval prolongation >60 ms did not differ (1.2% versus 0.5%). 

Chang MH, Kish TD, Fung HB. Telavancin a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by grampositive bacteria in adults. Clin Ther 2010 32(13) 2160-85. 

---